Delivery Order SPE2DE21D7010-SPE2D626F13G4

Nuvasive, Inc., a San Diego-based medical device manufacturer and subsidiary of Transplant Technology Inc.'s Bone Bank Allografts division, was awarded a delivery order for allograft products valued at $1,685.40 by the Defense Logistics Agency (DLA) Medical Supply Chain on December 11, 2025. The contract is structured as a fixed-price delivery order with economic price adjustment mechanisms and carries an ultimate completion date of January 2, 2026. This award was made through open market competition with no set-aside designation, reflecting Nuvasive's established competitive position as a supplier of specialized spinal and orthopedic surgical technologies to federal healthcare agencies.

This delivery order is issued against Nuvasive's participation in the DLA Medical Supply Chain procurement framework, which supplies medical devices and biologics to Department of Defense and Department of Veterans Affairs healthcare facilities. Nuvasive's portfolio includes an extensive range of spinal fusion devices, interbody implants, bone graft materials, and specialized surgical instruments. The company operates under a broader $8 million Blanket Purchase Agreement with the Defense Health Agency (an Indefinite Delivery/Indefinite Quantity vehicle effective through March 2027) and maintains a $48.97 million Indefinite Delivery Contract through the parent company Transplant Technology Inc. with the DLA Troop Support Medical division, both of which facilitate streamlined procurement of advanced orthopedic and neurosurgical technologies across the military health system.